Advances in HER3 ADC Development for Head and Neck Squamous Cell Carcinoma (HNSCC): Latest Clinical Research and Future Perspectives

In recent years, antibody-drug conjugates (ADCs) have emerged as one of the most promising therapeutic innovations in precision oncology. Following the remarkable clinical success of HER2-targeted ADCs and TROP2-targeted ADCs, the ADC field has continued to expand toward novel therapeutic targets. Among these, HER3-targeted antibody-drug conjugates (HER3 ADCs) have attracted growing attention as a potential treatment strategy for head and neck squamous cell carcinoma (HNSCC).

Human epidermal growth factor receptor 3 (HER3, also known as ERBB3) is widely expressed across multiple solid tumors and has been closely associated with tumor progression, therapeutic resistance, and poor clinical outcomes in patients with HNSCC. As several HER3 ADC candidates continue to advance through clinical development, increasing evidence suggests that they may offer new treatment opportunities for patients with advanced or recurrent HNSCC.

Drawing upon recently published clinical studies, presentations from major international oncology conferences, and the latest advances in innovative drug development, DengYueMed provides a comprehensive overview of the biological rationale, mechanisms of action, leading drug candidates, current clinical progress, and future prospects of HER3 ADCs in HNSCC, helping readers gain a deeper understanding of this rapidly evolving therapeutic approach.

---

What Is a HER3 ADC?

HER3 (ERBB3) is one of the four members of the human epidermal growth factor receptor (HER/ERBB) family, together with HER1 (EGFR), , and HER4. These receptors play critical roles in regulating cellular proliferation, differentiation, survival, and signaling pathways involved in both normal physiology and cancer development.

Unlike , HER3 possesses minimal intrinsic tyrosine kinase activity. However, it readily forms heterodimers with HER2 or EGFR, leading to activation of downstream signaling pathways such as PI3K/AKT and MAPK. These pathways promote tumor cell proliferation, invasion, metastasis, and resistance to therapy.

A HER3 antibody-drug conjugate (HER3 ADC) combines a monoclonal antibody specifically targeting HER3 with a highly potent cytotoxic payload through a specialized chemical linker. This design enables selective delivery of chemotherapy directly into HER3-expressing tumor cells while minimizing systemic exposure.

The major advantages of HER3 ADCs include:

• Selective recognition of HER3-expressing tumor cells
• Targeted intracellular delivery of highly potent cytotoxic agents
• Reduced damage to normal tissues compared with conventional chemotherapy
• The ability to eliminate neighboring tumor cells through the bystander effect, even in tumors with heterogeneous HER3 expression
• Potential to overcome resistance to EGFR-targeted therapies

For these reasons, HER3 ADCs are widely regarded as one of the most promising next-generation ADC platforms following the success of HER2-targeted ADCs.

Combination Strategies: The Future of HER3 ADC Therapy

Although HER3 ADCs have demonstrated encouraging efficacy as monotherapy, an increasing number of clinical studies are now focusing on combination treatment strategies to further improve patient outcomes.

HER3 ADC + PD-1 Inhibitors

Combining HER3 ADCs with immune checkpoint inhibitors may enhance antitumor immune responses by improving the tumor microenvironment and increasing immune cell infiltration.

This strategy has the potential to produce synergistic therapeutic effects, particularly in patients with recurrent or metastatic HNSCC.

HER3 ADC + EGFR Inhibitors

Since HER3 is one of the key mechanisms underlying resistance to EGFR-targeted therapies, combining HER3 ADCs with EGFR inhibitors may help overcome therapeutic resistance and improve treatment efficacy.

HER3 ADC + Radiotherapy

Radiotherapy remains a cornerstone of HNSCC treatment.

Preclinical studies suggest that HER3-targeted ADCs may enhance radiosensitivity, potentially leading to improved local tumor control and better long-term outcomes.

HER3 ADC + Chemotherapy

Combining HER3 ADCs with conventional chemotherapy may further increase objective response rates while delaying disease progression in patients with advanced HNSCC.

As ongoing clinical trials continue to report new data, these combination strategies may significantly improve:

• Objective Response Rate (ORR)
• Progression-Free Survival (PFS)
• Overall Survival (OS)

---

Challenges Facing HER3 ADC Development

Despite the promising therapeutic potential of HER3 ADCs, several important challenges remain before they can be widely incorporated into clinical practice.

1. Lack of Standardized HER3 Biomarker Assessment

There is currently no universally accepted standard for evaluating HER3 expression.

Differences in:

• Immunohistochemistry (IHC) assays
• Antibody selection
• Scoring systems
• Diagnostic platforms

may affect patient selection and treatment outcomes.

Establishing standardized HER3 testing criteria will be critical for future precision medicine.

---

2. Risk of Interstitial Lung Disease (ILD)

Several HER3 ADCs utilize DXd-based payloads, which have demonstrated remarkable antitumor activity.

However, similar to HER2-targeted DXd ADCs, interstitial lung disease (ILD) remains an important safety concern that requires careful monitoring during treatment.

Early recognition and prompt management of ILD are essential for optimizing patient safety and maintaining treatment continuity.

---

3. Mechanisms of Acquired Resistance

As with other targeted therapies, acquired resistance to HER3 ADCs may eventually develop during long-term treatment.

Potential resistance mechanisms include:

• Downregulation of HER3 expression
• Reduced ADC internalization
• Increased drug efflux
• Alterations in intracellular drug metabolism

Further research is needed to identify effective strategies for overcoming resistance and extending treatment benefit.

---

4. Identification of Predictive Biomarkers

Future patient selection is expected to increasingly rely on comprehensive biomarker profiling, including:

• HER3 protein expression
• Circulating tumor DNA (ctDNA)
• Next-generation genomic sequencing
• AI-assisted digital pathology

Integrating multiple biomarkers may improve patient stratification and maximize the clinical benefit of HER3-targeted therapies.

---

Future Perspectives

As ADC technology continues to evolve, HER3-targeted ADCs are expected to become an increasingly important component of precision therapy for HNSCC.

Future research is likely to focus on several key areas:

• Developing next-generation payloads with greater efficacy and lower toxicity
• Optimizing linker technologies to improve drug stability and controlled payload release
• Exploring combination regimens with immunotherapy, radiotherapy, chemotherapy, and targeted therapies
• Establishing robust biomarker-based patient selection strategies
• Expanding global multicenter Phase III clinical trials to accelerate regulatory approval and clinical implementation

With an increasing amount of clinical evidence becoming available, HER3 ADCs are expected not only to improve outcomes for patients with recurrent or metastatic HNSCC but also to reshape the future treatment landscape of head and neck cancer.

---

DengYueMed: Supporting Global Access to Precision Oncology

As precision oncology continues to evolve, international patients increasingly seek access to innovative therapies, experienced cancer specialists, and clinical trial opportunities.

DengYueMed is committed to helping patients connect with China’s rapidly advancing oncology ecosystem by providing compliant pharmaceutical supply services and cross-border medical coordination.

Our services include:

• Access to innovative oncology medicines through compliant pharmaceutical channels
• International hospital referral and medical coordination
• Assistance with multidisciplinary team (MDT) consultations
• Information on eligible clinical trial opportunities
• Cross-border medication logistics and patient support
• Personalized treatment resource consultation

Our goal is to help international patients access high-quality oncology resources safely, efficiently, and in compliance with applicable regulations.

---

Conclusion

HER3-targeted antibody-drug conjugates (HER3 ADCs) represent one of the most promising advances in next-generation ADC technology and offer new hope for patients with head and neck squamous cell carcinoma (HNSCC).

From Patritumab Deruxtecan (HER3-DXd) to innovative candidates such as BL-B01D1 and DB-1310, HER3 ADC development is progressing rapidly, with encouraging clinical data continuing to emerge.

Although challenges remain—including optimal patient selection, resistance mechanisms, biomarker standardization, and long-term safety management—the continuous evolution of ADC technologies, combination treatment strategies, and precision medicine is expected to further expand the clinical value of HER3-targeted therapies.

Looking ahead, HER3 ADCs have the potential to become an important therapeutic option for patients with recurrent or metastatic HNSCC, improving both survival outcomes and quality of life.

---

Disclaimer

This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

The information presented is based on publicly available scientific literature, international clinical guidelines, oncology conference presentations, and ongoing clinical research. Treatment decisions should always be made by qualified healthcare professionals based on each patient’s individual medical condition.

DengYueMed does not provide medical diagnosis or direct treatment services. We facilitate compliant access to pharmaceutical resources and international medical coordination for patients seeking cancer care.

---

References

1. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers (Latest Version)
2. ESMO Clinical Practice Guidelines for Head and Neck Squamous Cell Carcinoma
3. ASCO Educational Updates on Head and Neck Cancer
4. KEYNOTE-048 Clinical Trial
5. Recent publications on HER3-DXd (Patritumab Deruxtecan)
6. Recent publications on BL-B01D1 and next-generation HER3 ADC development
7. International Conference Presentations (ASCO, ESMO, AACR)